2015 American Transplant Congress
CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers
Blocking the CD40-CD154 pathway has been shown to effectively prolong renal allograft survival in non-human primates. CFZ533 is a novel, fully human, Fc-silent, anti-CD40 monoclonal…2015 American Transplant Congress
Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept
1Surgery, Duke University, Durham, NC; 2Transplant Center, Emory University, Atlanta, GA.
Belatacept offers highly specific costimulation blockade to prevent recipient alloimmune responses with reduced toxicity. However, when applied with nondepletional induction therapy belatacept-based regimens have higher…2015 American Transplant Congress
Clinical and Pathologic Predictors of Response to Belatacept Conversion
Columbia Universtiy, New York.
INTRO: Calcineurin inhibitors have improved kidney transplant and recipient survival, their use has significant nephrotoxicity. Belatacept is a recently approved immunosuppressant that is not nephrotoxic…2015 American Transplant Congress
Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Abatacept which is a co-stimulation inhibitor has been suggested to have B7-1 mediated antiproteinuric effects. Belatacept which is another co-stimulation agent has been approved…2015 American Transplant Congress
Independent Prognostic Factors for Survival in Hepatocellular Carcinoma Patients Undergoing Orthotopic Liver Transplantation: UNOS Population Study
Background: The impact of regional differences in bridging locoregional therapy (LRT) use and wait times on overall survival (OS) in hepatocellular carcinoma (HCC) patients undergoing…2015 American Transplant Congress
Refinement of Non-Invasive Diagnostic Criteria to Differentiate Tumor from Bland Portal Vein Thrombosis Before Liver Transplant in Patients With Hepatocellular Carcinoma
University of California San Francisco, San Francisco, CA.
Differentiating tumor vs bland portal vein thrombosis (PVT) is essential in determining liver transplant (LT) candidacy for patients with hepatocellular carcinoma (HCC). The primary aim…2015 American Transplant Congress
The Extended Toronto Criteria for Transplantation for Hepatocellular Carcinoma. A Validation Study
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
Liver transplant (LT) listing criteria for patients with hepatocellular cancers (HCC) that exceed the Milan criteria are still controversial. At the University of Toronto, we…2015 American Transplant Congress
Pretransplant Elevated Plasma Fibrinogen Level Is Associated With Tumor Recurrence and Poor Prognosis in Hepatocellular Carcinoma Patients After Liver Transplantation
Background and Objective: Elevated plasma fibrinogen (FBG) level is associated with tumor progression and poor patient outcomes in several cancers. The aim of this study…2015 American Transplant Congress
Predictors of Time to Recurrence and Mortality Associated With Recurrent Hepatocellular Carcinoma After Liver Transplantation
Transplantation, UCLA, Los Angeles, CA.
Background: While recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) portends a poor prognosis, adjuvant therapy may prolong survival. We sought to identify factors that…2015 American Transplant Congress
Multicenter Study to Develop a Novel Prediction Index for Hepatocellular Carcinoma (HCC) Recurrence After Liver Transplant (LT)
1UCSF, San Francisco, CA; 2Mayo Clinic, Rochester, MN; 3Mayo Clinic, Jacksonville, FL.
Several factors have been associated with a high risk of recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT), but no reliable risk score has…
American Transplant Congress abstracts